Published in Oncoimmunology on July 01, 2012
CD8(+) T cell response to adenovirus vaccination and subsequent suppression of tumor growth: modeling, simulation and analysis. BMC Syst Biol (2015) 1.12
Immunotherapy-induced CD8+ T cells instigate immune suppression in the tumor. Mol Ther (2013) 1.04
Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes. Int J Oncol (2014) 0.93
Oncolytic vesicular stomatitis virus quantitatively and qualitatively improves primary CD8(+) T-cell responses to anticancer vaccines. Oncoimmunology (2013) 0.88
Human Tumor Antigens and Cancer Immunotherapy. Biomed Res Int (2015) 0.81
CD137 and CD137L signals are main drivers of type 1, cell-mediated immune responses. Oncoimmunology (2015) 0.81
Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors. Vaccines (Basel) (2016) 0.78
Next Generation Vaccine Biomarkers workshop October 30-31, 2014 - Ottawa, Canada. Hum Vaccin Immunother (2015) 0.75
Inferring the Impact of Regulatory Mechanisms that Underpin CD8+ T Cell Control of B16 Tumor Growth In vivo Using Mechanistic Models and Simulation. Front Pharmacol (2017) 0.75
SCIB1, a huIgG1 antibody DNA vaccination, combined with PD-1 blockade induced efficient therapy of poorly immunogenic tumors. Oncotarget (2016) 0.75
Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics (2003) 100.88
Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A (2002) 30.32
Restoring function in exhausted CD8 T cells during chronic viral infection. Nature (2005) 28.04
Death receptors: signaling and modulation. Science (1998) 16.95
Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. Science (1993) 14.91
TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol (2005) 7.44
The B7-CD28 superfamily. Nat Rev Immunol (2002) 7.24
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A (2010) 6.20
Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood (2009) 6.17
The PD-1 pathway in tolerance and autoimmunity. Immunol Rev (2010) 5.99
Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature (1994) 5.58
Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med (1997) 3.89
Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis (2003) 3.73
4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J Exp Med (1997) 3.31
PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res (2007) 3.23
Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors. Clin Cancer Res (2009) 2.97
The balance of reproducibility, sensitivity, and specificity of lists of differentially expressed genes in microarray studies. BMC Bioinformatics (2008) 2.54
Features of responding T cells in cancer and chronic infection. Curr Opin Immunol (2010) 2.42
Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. Proc Natl Acad Sci U S A (2009) 2.32
Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J Clin Invest (2002) 2.21
Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome. Clin Cancer Res (2010) 2.01
Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma. J Immunol (2010) 1.98
Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal. J Immunol (1999) 1.95
Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment. Curr Opin Immunol (2010) 1.84
Immune responses in 4-1BB (CD137)-deficient mice. J Immunol (2002) 1.74
New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site. J Immunol (2006) 1.74
A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer. Breast Cancer Res (2010) 1.50
IFN-gamma and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy. J Clin Invest (2001) 1.30
4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner. J Immunol (2002) 1.29
Cross-talk between programmed death-1 and suppressor of cytokine signaling-1 in inhibition of IL-12 production by monocytes/macrophages in hepatitis C virus infection. J Immunol (2011) 1.26
An enhanced system for construction of adenoviral vectors by the two-plasmid rescue method. Hum Gene Ther (2000) 1.23
Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb. Clin Immunol (2007) 1.19
Targeting inhibitory pathways in cancer immunotherapy. Curr Opin Immunol (2010) 1.10
Mechanisms involved in synergistic anticancer immunity of anti-4-1BB and anti-CD4 therapy. Cancer Res (2007) 1.08
Vaccination-induced autoimmune vitiligo is a consequence of secondary trauma to the skin. Cancer Res (2004) 1.08
Optimising anti-tumour CD8 T-cell responses using combinations of immunomodulatory antibodies. Eur J Immunol (2008) 1.03
Recombinant viral vectors: cancer vaccines. Adv Drug Deliv Rev (2006) 0.99
4-1BB signaling beyond T cells. Cell Mol Immunol (2011) 0.99
Neoadjuvant vaccination provides superior protection against tumor relapse following surgery compared with adjuvant vaccination. Cancer Res (2009) 0.97
Elevated frequencies of self-reactive CD8+ T cells following immunization with a xenoantigen are due to the presence of a heteroclitic CD4+ T-cell helper epitope. Cancer Res (2007) 0.97
Plasmid DNA and viral vector-based vaccines for the treatment of cancer. Vaccine (2007) 0.95
High-dose chemotherapy augments the efficacy of recombinant adenovirus vaccines and improves the therapeutic outcome. Cancer Gene Ther (2008) 0.92
Immunity to melanoma mediated by 4-1BB is associated with enhanced activity of tumour-infiltrating lymphocytes. Immunol Cell Biol (2005) 0.87
CTL-dependent and -independent antitumor immunity is determined by the tumor not the vaccine. J Immunol (2004) 0.86
Programmed death (PD)-1-deficient mice are extremely sensitive to murine hepatitis virus strain-3 (MHV-3) infection. PLoS Pathog (2011) 0.85
Processing of tumor antigen differentially impacts the development of helper and effector CD4+ T-cell responses. Mol Ther (2010) 0.78
Biological, clinical and population relevance of 95 loci for blood lipids. Nature (2010) 28.21
Targeted disruption of beta1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction. Cancer Cell (2004) 4.34
Loci related to metabolic-syndrome pathways including LEPR,HNF1A, IL6R, and GCKR associate with plasma C-reactive protein: the Women's Genome Health Study. Am J Hum Genet (2008) 4.31
Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells. Cell (2012) 4.13
Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet (2012) 3.21
Research capacity. Enabling the genomic revolution in Africa. Science (2014) 3.05
ERM is required for transcriptional control of the spermatogonial stem cell niche. Nature (2005) 2.58
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
TNF-alpha is a critical negative regulator of type 1 immune activation during intracellular bacterial infection. J Clin Invest (2004) 1.76
FGF-regulated Etv genes are essential for repressing Shh expression in mouse limb buds. Dev Cell (2009) 1.53
Myocardial injury after noncardiac surgery: a large, international, prospective cohort study establishing diagnostic criteria, characteristics, predictors, and 30-day outcomes. Anesthesiology (2014) 1.47
Potentiating cancer immunotherapy using an oncolytic virus. Mol Ther (2010) 1.46
What is the impact of primary care model type on specialist referral rates? A cross-sectional study. BMC Fam Pract (2014) 1.41
Nonlinear response of summer temperature to Holocene insolation forcing in Alaska. Proc Natl Acad Sci U S A (2011) 1.40
Human protein arginine methyltransferase 7 (PRMT7) is a type III enzyme forming ω-NG-monomethylated arginine residues. J Biol Chem (2012) 1.38
Interactions between the immune system and cancer: a brief review of non-spatial mathematical models. Bull Math Biol (2010) 1.33
Antigen presentation by exosomes released from peptide-pulsed dendritic cells is not suppressed by the presence of active CTL. J Immunol (2007) 1.32
A switch in costimulation from CD28 to 4-1BB during primary versus secondary CD8 T cell response to influenza in vivo. J Immunol (2004) 1.28
Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus. Mol Ther (2009) 1.22
Blood CD33(+)HLA-DR(-) myeloid-derived suppressor cells are increased with age and a history of cancer. J Leukoc Biol (2013) 1.22
Cigarette smoke impairs NK cell-dependent tumor immune surveillance. J Immunol (2007) 1.18
Cutting edge: dendritic epidermal γδ T cell ligands are rapidly and locally expressed by keratinocytes following cutaneous wounding. J Immunol (2012) 1.15
HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy. Mol Ther (2013) 1.13
Adaptive antiviral immunity is a determinant of the therapeutic success of oncolytic virotherapy. Mol Ther (2010) 1.12
Engineering dendritic cells to enhance cancer immunotherapy. Mol Ther (2011) 1.10
Common genetic loci influencing plasma homocysteine concentrations and their effect on risk of coronary artery disease. Am J Clin Nutr (2013) 1.08
Vaccination-induced autoimmune vitiligo is a consequence of secondary trauma to the skin. Cancer Res (2004) 1.08
Self-reported medication adherence and symptom experience in adults with HIV. J Assoc Nurses AIDS Care (2011) 1.07
A gene signature for predicting outcome in patients with basal-like breast cancer. Sci Rep (2012) 1.06
Mesenchymal stromal cells cross-present soluble exogenous antigens as part of their antigen-presenting cell properties. Blood (2009) 1.06
Interpreting metabolomic profiles using unbiased pathway models. PLoS Comput Biol (2010) 1.05
Climatic and land cover influences on the spatiotemporal dynamics of Holocene boreal fire regimes. Ecology (2013) 1.04
Recent advances in the development of adenovirus- and poxvirus-vectored tuberculosis vaccines. Curr Gene Ther (2005) 1.04
The polyfunctionality of human memory CD8+ T cells elicited by acute and chronic virus infections is not influenced by age. PLoS Pathog (2012) 1.03
Persistence of transgene expression influences CD8+ T-cell expansion and maintenance following immunization with recombinant adenovirus. J Virol (2009) 1.02
Stem cell research ethics: consensus statement on emerging issues. J Obstet Gynaecol Can (2007) 1.02
On the role of CD4+ T cells in the CD8+ T-cell response elicited by recombinant adenovirus vaccines. Mol Ther (2007) 1.01
Optimizing vaccine-induced CD8(+) T-cell immunity: focus on recombinant adenovirus vectors. Expert Rev Vaccines (2011) 1.00
Function of PEA3 Ets transcription factors in mammary gland development and oncogenesis. J Mammary Gland Biol Neoplasia (2003) 1.00
Recombinant vesicular stomatitis virus transduction of dendritic cells enhances their ability to prime innate and adaptive antitumor immunity. Mol Ther (2009) 1.00
Scale-up of breast cancer stem cell aggregate cultures to suspension bioreactors. Biotechnol Prog (2006) 0.99
Exploring gene-environment relationships in cardiovascular disease. Can J Cardiol (2013) 0.99
Cutaneous antigen priming via gene gun leads to skin-selective Th2 immune-inflammatory responses. J Immunol (2005) 0.98
Targeted inhibition of serotonin type 7 (5-HT7) receptor function modulates immune responses and reduces the severity of intestinal inflammation. J Immunol (2013) 0.98
Neoadjuvant vaccination provides superior protection against tumor relapse following surgery compared with adjuvant vaccination. Cancer Res (2009) 0.97
IL-15 and type I interferon are required for activation of tumoricidal NK cells by virus-infected dendritic cells. Cancer Res (2011) 0.97
Elevated frequencies of self-reactive CD8+ T cells following immunization with a xenoantigen are due to the presence of a heteroclitic CD4+ T-cell helper epitope. Cancer Res (2007) 0.97
Small molecule antagonists of the Wnt/β-catenin signaling pathway target breast tumor-initiating cells in a Her2/Neu mouse model of breast cancer. PLoS One (2012) 0.96
The memory T cell response to West Nile virus in symptomatic humans following natural infection is not influenced by age and is dominated by a restricted set of CD8+ T cell epitopes. J Immunol (2008) 0.96
Enhanced antitumor immunity elicited by dendritic cell vaccines is a result of their ability to engage both CTL and IFN gamma-producing NK cells. Mol Ther (2007) 0.95
Pea3 transcription factors and wnt1-induced mouse mammary neoplasia. PLoS One (2010) 0.94
T-cell immunity generated by recombinant adenovirus vaccines. Expert Rev Vaccines (2007) 0.93
Aberrant brain activation during a working memory task in psychotic major depression. Am J Psychiatry (2010) 0.93
Distinguishing West Nile virus infection using a recombinant envelope protein with mutations in the conserved fusion-loop. BMC Infect Dis (2014) 0.93
The Pea3 Ets transcription factor regulates differentiation of multipotent progenitor cells during mammary gland development. Dev Biol (2008) 0.92
An algorithm to discover gene signatures with predictive potential. J Exp Clin Cancer Res (2010) 0.92
Luteolin is a novel p90 ribosomal S6 kinase (RSK) inhibitor that suppresses Notch4 signaling by blocking the activation of Y-box binding protein-1 (YB-1). Oncotarget (2013) 0.91
The effectiveness of opioid substitution treatments for patients with opioid dependence: a systematic review and multiple treatment comparison protocol. Syst Rev (2014) 0.89
A novel computer algorithm improves antibody epitope prediction using affinity-selected mimotopes: a case study using monoclonal antibodies against the West Nile virus E protein. Mol Immunol (2008) 0.88
Oncolytic vesicular stomatitis virus quantitatively and qualitatively improves primary CD8(+) T-cell responses to anticancer vaccines. Oncoimmunology (2013) 0.88
E2F1 and KIAA0191 expression predicts breast cancer patient survival. BMC Res Notes (2011) 0.88
Immunotherapy can reject intracranial tumor cells without damaging the brain despite sharing the target antigen. J Immunol (2010) 0.88
Tolerogenic dendritic cells and their potential applications. Immunology (2011) 0.88
A phase I trial of adenovector-mediated delivery of interleukin-2 (AdIL-2) in high-risk localized prostate cancer. Cancer Gene Ther (2003) 0.88
Activation of the WT1 tumor suppressor gene promoter by Pea3. FEBS Lett (2004) 0.88
Autophagy facilitates major histocompatibility complex class I expression induced by IFN-γ in B16 melanoma cells. Cancer Immunol Immunother (2010) 0.88
Surface phenotype and functionality of WNV specific T cells differ with age and disease severity. PLoS One (2010) 0.87
FoxG1 interacts with Bmi1 to regulate self-renewal and tumorigenicity of medulloblastoma stem cells. Stem Cells (2013) 0.87
Identification of Cadherin 2 (CDH2) Mutations in Arrhythmogenic Right Ventricular Cardiomyopathy. Circ Cardiovasc Genet (2017) 0.87
Plant-produced trastuzumab inhibits the growth of HER2 positive cancer cells. J Agric Food Chem (2010) 0.87
Multi-stability and multi-instability phenomena in a mathematical model of tumor-immune-virus interactions. Bull Math Biol (2011) 0.87
CTL-dependent and -independent antitumor immunity is determined by the tumor not the vaccine. J Immunol (2004) 0.86
Deciphering epitope specificities within polyserum using affinity selection of random peptides and a novel algorithm based on pattern recognition theory. Mol Immunol (2008) 0.86
Adenoviral-mediated gene transfer of lymphotactin to the lungs of mice and rats results in infiltration and direct accumulation of CD4+, CD8+, and NK cells. J Interferon Cytokine Res (2002) 0.86
Mucosally delivered dendritic cells activate T cells independently of IL-12 and endogenous APCs. J Immunol (2008) 0.86
Tumor protection following vaccination with low doses of lentivirally transduced DCs expressing the self-antigen erbB2. Mol Ther (2008) 0.86
Delivery of viral-vectored vaccines by B cells represents a novel strategy to accelerate CD8(+) T-cell recall responses. Blood (2013) 0.85
A cancer stem cell model for studying brain metastases from primary lung cancer. J Natl Cancer Inst (2013) 0.85
Does genetic heterogeneity account for the divergent risk of type 2 diabetes in South Asian and white European populations? Diabetologia (2014) 0.84